Last updated: August 28, 2026
Alfuzosin hydrochloride is a mature, off-patent alpha-1 adrenergic antagonist used to treat the symptoms of benign prostatic hyperplasia (BPH). Its commercial value has shifted from branded product economics to low-cost generic volume. U.S. sales are fragmented across generic manufacturers, while Sanofi’s branded Uroxatral and international Xatral products have limited strategic importance compared with newer BPH therapies.
The principal market risks are generic price erosion, substitution by tamsulosin and other alpha blockers, and increasing use of 5-alpha-reductase inhibitors or fixed treatment strategies for patients with enlarged prostates. The principal commercial opportunity is stable chronic demand from an aging male population, particularly in markets where alfuzosin remains available at a price premium to older nonselective agents.
What is alfuzosin hydrochloride used for?
Alfuzosin hydrochloride is an oral alpha-1 adrenergic receptor antagonist indicated for the treatment of signs and symptoms of BPH. The extended-release formulation relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing lower urinary tract symptoms.
The U.S. branded product, Uroxatral extended-release tablets, contains 10 mg of alfuzosin hydrochloride and is administered once daily after the same meal each day. The FDA approved Uroxatral in June 2003 under NDA 021287. The approved indication is symptomatic treatment of BPH in men, not treatment of hypertension or prostate cancer (FDA, 2003).
Alfuzosin competes in a therapeutic category that includes:
- Tamsulosin
- Silodosin
- Doxazosin
- Terazosin
- Finasteride
- Dutasteride
- Combination products such as tamsulosin/dutasteride
Its clinical positioning is based on urinary symptom relief with less ejaculatory dysfunction than some highly selective alpha-1A agents, although dizziness, hypotension and syncope remain relevant safety concerns.
How large is the alfuzosin hydrochloride market?
The total alfuzosin hydrochloride market is a mature generic market with limited transparent product-level revenue reporting. Public-company filings generally combine alfuzosin with broader generic portfolios, preventing reliable standalone global sales estimates.
The market has four commercial characteristics:
| Market characteristic |
Effect on alfuzosin economics |
| Mature molecule |
Limits pricing power and innovation returns |
| Generic availability |
Creates rapid price competition |
| Chronic BPH use |
Supports recurring prescription volume |
| Therapeutic substitution |
Caps long-term share growth |
Branded Uroxatral sales declined after generic entry. Generic manufacturers now supply most U.S. volume, and wholesale acquisition cost is materially below the branded product’s historical price. In many markets, alfuzosin is priced above older nonselective alpha blockers but below branded or newer selective alternatives.
The relevant economic measure is therefore prescription volume multiplied by a low generic net price, rather than premium branded revenue. Market growth is more closely linked to diagnosis rates, physician prescribing habits, reimbursement policy and population aging than to product innovation.
When did alfuzosin lose market exclusivity?
Alfuzosin lost practical U.S. market exclusivity after the expiration of its core patent and regulatory exclusivity protections. The FDA approved generic extended-release alfuzosin products beginning in 2010, including products referencing Uroxatral.
The principal timeline is:
| Event |
Date |
Commercial consequence |
| Uroxatral FDA approval |
June 26, 2003 |
Branded U.S. launch |
| Initial U.S. regulatory exclusivity period |
Expired in the mid-2000s |
Generic filing pathway opened |
| Generic extended-release approvals |
From 2010 |
Branded price and share pressure |
| Current U.S. market |
Generic-dominated |
Limited branded pricing power |
Uroxatral’s branded exclusivity period was short relative to newer specialty medicines. Alfuzosin is now treated as an off-patent small molecule in the United States and Europe.
What patents protect alfuzosin hydrochloride?
No material active U.S. patent estate is generally associated with alfuzosin hydrochloride as a commercial product today. The original compound, salt, formulation and extended-release technology patents were filed many years before generic entry and have expired or ceased to be commercially blocking.
The historical patent estate covered:
- Alfuzosin and pharmaceutically acceptable salts
- Extended-release oral tablets
- Controlled-release delivery characteristics
- Treatment of urinary symptoms associated with BPH
- Manufacturing and formulation processes
The economic value of these rights has ended in the United States. Any current patent risk would more likely arise from a newly developed formulation, combination product, device or jurisdiction-specific process patent rather than from standard alfuzosin hydrochloride tablets.
The FDA Orange Book is the relevant source for active listed patents covering approved U.S. drug products. A current Orange Book review should be used to confirm listing status for a specific abbreviated new drug application or product presentation because listings can change by product and dosage form (FDA, 2025a).
What is the Orange Book status of alfuzosin?
Alfuzosin is an approved small-molecule prescription drug with generic extended-release tablet competition. The Orange Book status is commercially significant mainly for historical reference because the product is no longer protected by a blocking U.S. patent estate.
Relevant regulatory characteristics include:
- Reference product: Uroxatral extended-release tablets
- Reference NDA: 021287
- Dosage form: Extended-release tablet
- Strength: 10 mg
- Generic pathway: ANDA approval
- Biosimilar pathway: Not applicable
- Current commercial status: Generic competition
A generic manufacturer seeking approval would ordinarily rely on an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product. Alfuzosin does not require the clinical development program associated with a new molecular entity.
Which companies manufacture alfuzosin hydrochloride?
Manufacturing is fragmented across generic pharmaceutical companies and contract manufacturers. Companies that have marketed or obtained U.S. approvals for generic alfuzosin products have included large generic manufacturers and smaller specialty-generic firms. The exact active supplier set varies by country, dosage strength, supply contract and time period.
The competitive structure has three levels:
Finished-dose manufacturers
These companies hold or commercialize ANDAs for extended-release tablets. They compete through formulary access, supply reliability, contract pricing and manufacturing cost.
Active pharmaceutical ingredient suppliers
Alfuzosin hydrochloride API is manufactured by specialized chemical and pharmaceutical suppliers, primarily serving generic finished-dose producers. API economics are typically characterized by multiple qualified sources and limited differentiation.
Branded and regional licensees
Sanofi historically commercialized Uroxatral in the United States and Xatral in international markets. Regional distributors and licensees have supported availability outside the United States, but the product lacks the global commercial leverage of a protected branded medicine.
How strong is the alfuzosin patent estate?
The current patent estate is weak from a market-exclusivity perspective. The molecule is old, generic competition is established, and the extended-release product has been commercially copied.
Patent strength can be assessed as follows:
| Patent category |
Current strategic strength |
| Original compound patent |
Expired |
| Salt patent |
Expired or commercially nonblocking |
| Extended-release formulation patent |
Expired or no longer sufficient to prevent competition |
| Method-of-use patent |
Limited practical value for standard BPH treatment |
| Manufacturing patent |
Potentially narrow and supplier-specific |
| New combination patent |
Could create incremental protection if independently approved |
A patent covering an improved formulation could have value only if it delivered clinically meaningful benefits and obtained regulatory approval for a differentiated product. A conventional once-daily alfuzosin tablet would face substantial invalidity, obviousness and infringement challenges if marketed under a newly asserted formulation theory.
What formulation patents protect alfuzosin products?
Historical formulation protection focused on extended-release oral delivery. The commercial purpose was to produce sustained alfuzosin exposure from a once-daily tablet while limiting peak-related adverse events.
Potential formulation claims can cover:
- Polymer matrices
- Coated multiparticulates
- Release-rate profiles
- Tablet excipient systems
- Food-effect control
- Dose uniformity
- Manufacturing processes for extended-release tablets
These technologies are no longer a strong barrier to standard generic entry. A new product would need either a different release profile, improved tolerability, a combination with another BPH medicine or a novel delivery route to justify meaningful development investment.
What method-of-use patents cover alfuzosin?
Alfuzosin’s principal use is symptomatic treatment of BPH. That indication is well established and does not provide a strong current exclusivity platform.
Potential method-of-use claims could address:
- Treatment of lower urinary tract symptoms
- Use in patients with cardiovascular comorbidities
- Perioperative urinary retention
- Combination treatment with finasteride or dutasteride
- Patient subgroups defined by prostate size or symptom severity
Such claims would face practical enforcement limits. Physicians may prescribe generic alfuzosin for an unpatented indication, and generic labeling strategies can create complex litigation issues. The commercial value of a narrow method-of-use patent would depend on prescribing concentration, label language and the ability to prove induced infringement.
Have companies filed Paragraph IV challenges against alfuzosin?
Generic entry into alfuzosin has already occurred, so historical Paragraph IV disputes are more relevant than future launch barriers. A Paragraph IV certification allows an ANDA applicant to assert that an Orange Book-listed patent is invalid, unenforceable or not infringed.
The typical sequence would have been:
- ANDA submission referencing Uroxatral.
- Paragraph IV notice to the NDA holder or patent owner.
- Potential patent litigation within the statutory period.
- A 30-month stay of FDA approval if the statutory conditions were satisfied.
- Approval after patent resolution, settlement or expiration.
Because the principal U.S. patents have expired and generic products are already marketed, new Paragraph IV litigation is unlikely to materially alter the U.S. market structure. Any future dispute would likely involve a specific formulation, supplier process or newly approved combination product rather than ordinary alfuzosin extended-release tablets.
What litigation and settlement agreements affect alfuzosin?
Alfuzosin does not have a current litigation profile comparable with high-value branded medicines such as GLP-1 agonists, oncology biologics or specialty immunology products. Historical patent litigation may have accompanied generic ANDA filings, but the commercial outcome is already reflected in the genericized market.
No widely reported current settlement structure appears to preserve meaningful branded market exclusivity for standard alfuzosin tablets. Any historical agreement must be reviewed against the specific patent, ANDA applicant and launch date because settlement terms can include licenses, authorized generic provisions, launch dates and manufacturing restrictions.
For present investment analysis, litigation is a low-priority risk factor unless a company is developing a differentiated alfuzosin formulation.
Is alfuzosin exposed to biosimilar competition?
No. Alfuzosin hydrochloride is a chemically synthesized small molecule, not a biologic. It is exposed to generic competition through the ANDA pathway, not biosimilar competition under the Public Health Service Act.
The relevant competitive risks are:
- Generic price compression
- Multiple-source substitution
- Formulary exclusion
- Therapeutic substitution
- API supply interruptions
- Product recalls or manufacturing deficiencies
This distinction matters because biosimilar markets can retain higher prices and greater manufacturer concentration, while mature small-molecule markets typically experience faster price erosion after generic entry.
How does alfuzosin compare with tamsulosin?
Tamsulosin is the stronger direct competitor in many markets because of physician familiarity, broad generic availability and selective alpha-1A activity. Alfuzosin retains a role where clinicians value its symptom profile or seek an alternative for patients who experience adverse effects with tamsulosin.
| Factor |
Alfuzosin |
Tamsulosin |
| Drug class |
Alpha-1 blocker |
Alpha-1A-preferring blocker |
| Common use |
BPH symptoms |
BPH symptoms |
| U.S. branded reference |
Uroxatral |
Flomax |
| Generic status |
Mature generic |
Mature generic |
| Dosing |
Commonly once daily extended-release |
Commonly once daily |
| Commercial position |
Secondary generic option |
High-volume generic option |
| Key safety concerns |
Dizziness, hypotension, syncope |
Ejaculatory dysfunction, dizziness |
| Growth outlook |
Stable to declining value |
Larger prescription base |
Silodosin competes on alpha-1A selectivity but often carries a higher price. Finasteride and dutasteride compete through prostate-volume reduction and are frequently used in patients with larger prostates or progressive disease risk.
What is the financial trajectory for alfuzosin?
The financial trajectory is characterized by a sharp historical decline followed by low-value stabilization.
Branded phase
Before generic entry, Uroxatral generated revenue from branded prescription pricing and physician recognition. Commercial value depended on the BPH market, product differentiation and Sanofi’s sales infrastructure.
Generic conversion phase
After generic approval, prices declined as multiple manufacturers entered. Pharmacy benefit managers and wholesalers gained negotiating leverage. Branded substitution reduced Uroxatral volume, while generic manufacturers competed for formulary placement and supply contracts.
Mature generic phase
Current revenue is distributed among manufacturers. Product-level financial disclosure is limited, and alfuzosin is usually immaterial within diversified generic portfolios. Profitability depends on:
- Manufacturing scale
- API acquisition cost
- Contract volume
- Regulatory compliance
- Shortage conditions
- Number of active competitors
- Reimbursement rates
The base case is stable prescription demand with declining or flat nominal market value. Volume can rise with population aging, but that increase is unlikely to offset long-term price erosion unless supply concentration or shortage conditions temporarily improve pricing.
What generic launch scenarios exist for alfuzosin?
The U.S. market is already in the post-launch generic phase. Future commercial scenarios are therefore incremental rather than transformational.
| Scenario |
Market effect |
| More generic entrants |
Lower prices and lower manufacturer margins |
| Supplier consolidation |
Higher shortage and pricing risk |
| Branded reformulation |
Possible niche premium, high development burden |
| Combination product |
Potential differentiation but regulatory and patent costs |
| Tamsulosin substitution |
Continued share pressure |
| Demand growth from aging |
Volume support without strong price growth |
A generic manufacturer can still earn acceptable returns if it has efficient extended-release manufacturing, reliable supply and low regulatory overhead. A new branded alfuzosin program would face weak economics unless it targets a clear clinical or adherence advantage.
What geographic markets offer the most opportunity?
Alfuzosin has the strongest remaining commercial relevance in markets with:
- Large aging male populations
- Persistent BPH diagnosis rates
- Generic reimbursement
- Physician familiarity with Xatral or Uroxatral
- Less aggressive substitution toward tamsulosin
- Limited access to newer BPH therapies
The United States is a low-price, highly genericized market. Europe and other international markets may support more durable branded or semi-branded sales, depending on national reimbursement and tender structures. Emerging markets can offer volume growth, but pricing is generally lower and local regulatory registration, distribution and manufacturing requirements can reduce returns.
Geographic patent protection is not a major current value driver. Regulatory registration, local manufacturing rules, tender access and pharmacovigilance compliance are more important than patent exclusion.
What manufacturing and intellectual-property barriers remain?
The principal barriers are operational rather than patent-based. Extended-release tablet production requires validated release characteristics, content uniformity, stability data and bioequivalence performance. Manufacturing changes can affect dissolution and exposure, creating regulatory risk even when patents have expired.
Commercial barriers include:
- FDA or other regulator inspection findings
- Limited qualified API suppliers
- Extended-release dissolution failures
- Product recalls
- Contract manufacturing capacity
- Tender qualification
- Pharmacovigilance obligations
These barriers can protect incumbent suppliers temporarily through reliability and market access, but they do not create durable exclusivity comparable with an active pharmaceutical patent.
Key Takeaways
- Alfuzosin hydrochloride is a mature generic BPH medicine with limited branded revenue potential.
- Uroxatral was approved by the FDA in 2003; generic extended-release products entered the U.S. market from 2010.
- The core compound, formulation and use patents are no longer meaningful commercial barriers in the United States.
- The product is subject to generic competition, not biosimilar competition.
- Tamsulosin is the main direct competitor and generally has stronger volume economics.
- Product-level revenue is not reliably disclosed because manufacturers report alfuzosin within broader generic portfolios.
- The financial outlook is stable-to-declining value, with chronic volume offset by price erosion.
- Manufacturing reliability, API sourcing and formulary access matter more than patent protection.
- A new alfuzosin investment would require a differentiated formulation, combination product or delivery technology to support premium pricing.
FAQs
Can alfuzosin hydrochloride still generate attractive generic margins?
Yes, but mainly for manufacturers with low-cost production, reliable supply or limited competition in a specific market. Standard U.S. generic margins are structurally constrained.
Is Uroxatral still commercially relevant?
Uroxatral has residual branded recognition, but generic alfuzosin has displaced most of its U.S. commercial value. Its relevance is greater in selected international markets.
Can alfuzosin be combined with finasteride or dutasteride?
Physicians may use alpha blockers with 5-alpha-reductase inhibitors, but a fixed-dose alfuzosin combination would require separate regulatory approval and could create new formulation and patent opportunities.
Does alfuzosin have pediatric or oncology market potential?
No established commercial indication supports a meaningful pediatric or oncology market for alfuzosin. Its principal market remains adult male BPH treatment.
What would increase alfuzosin market value?
A clinically validated formulation with improved tolerability, reduced food effect, better adherence or combination treatment could increase value. Standard generic tablets are unlikely to regain premium pricing.
References
-
European Medicines Agency. (n.d.). Xatral and alfuzosin product information. https://www.ema.europa.eu/
-
U.S. Food and Drug Administration. (2003). Uroxatral prescribing information and approval history, NDA 021287. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
-
U.S. Food and Drug Administration. (2025b). Drugs@FDA: Alfuzosin hydrochloride and Uroxatral. https://www.accessdata.fda.gov/scripts/cder/daf/
-
American Urological Association. (2023). Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia guideline. https://www.auanet.org/guidelines
-
National Center for Biotechnology Information. (2024). Alfuzosin hydrochloride drug information. PubChem. https://pubchem.ncbi.nlm.nih.gov/
